Recombinant Human Peptide Ready HLA-A*02:01&B2M Monomer Protein (HEK293)，Avi & His

The study of the Peptide Ready HLA-A*02:01&B2M monomer recombinant protein is crucial in the fields of immunology and vaccine development. HLA-A*02:01 is one of the most common human leukocyte antigen (HLA) class I molecules, playing a pivotal role in the immune response by presenting peptide antigens to CD8+ T cells. Its relevance is underscored by its association with various diseases, including viral infections and cancers. The B2M (beta-2-microglobulin) component is essential for the stability and surface expression of HLA class I molecules. Researchers have focused on creating a stable, recombinant form of HLA-A*02:01 complexed with B2M to facilitate the study of T cell responses and the development of peptide-based immunotherapies. By utilizing this monomer, scientists aim to enhance the understanding of T cell receptor interactions, evaluate the immunogenicity of specific peptide epitopes, and design novel vaccines that can elicit robust immune responses. Furthermore, the Peptide Ready HLA-A*02:01&B2M monomer serves as a platform for high-throughput screening of peptide libraries, enabling the identification of optimal vaccine candidates and therapeutic targets. The insights gained from this research could lead to innovative approaches for the prevention and treatment of infectious diseases and cancers, showcasing the importance of HLA-A*02:01 in personalized medicine and immunotherapy.